Mode
Text Size
Log in / Sign up
N/A N=39

ABCA3 Gene and RDS in Late Preterm and Term Infants

Respiratory Distress Syndrome, Newborn

Enrolled (actual)
39
Serious AEs
0.0%
Results posted
Aug 2021
Primary outcome: Primary: Mortality — 5; 3; 5 Participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
no intervention (Other)
Age
Pediatric
Sex
All
Sponsor
Children's Hospital of Chongqing Medical University
Primary completion
Dec 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Mortality
5; 3; 5
SECONDARY
the Onset of Respiratory Distress Syndrome
1.83; 4.6; 5.24
SECONDARY
the Age of Developing Severe RDS Marked With Oxygenation Index of 16
1.06; 5.3; 4.5
SECONDARY
Radiological Score
15.29; 12.90; 10.77; 15.14; 14.90; 13.23

Summary

Respiratory distress syndrome (RDS) is the most common respiratory cause of mortality and morbidity in very preterm infants, but it also could be seen in late preterm and term infants. Some genetic mechanisms were involved in the pathogenesis of RDS in late preterm and term infants. ATP-binding cassette transporter A3 (ABCA3) is essential for the production of pulmonary surfactant, whose mutation is the most common monogenetic cause of RDS in newborns. It also takes a vital role on unexplained RDS (URDS) in late preterm and term infants. Some previous studies showed that URDS with homozygous or compound heterozygous ABCA3 mutations had high mortality, while different mutation types could lead to different outcomes. However, most of the study focused on URDS with ABCA3 gene mutations, and there is no evidence that URDS without confirmed gene mutations have relatively better or worse outcomes. Furthermore, all the population in previous study are non-Asian races, which indicated that all the study conclusion is not applicable in Asia. Based on the next-generation sequencing technology, exome sequencing has been widely used in the clinic. In our neonatal intensive care unit (NICU), a clinic exome sequencing was usually performed in infants with fatal URDS. The present study was designed to compare the URDS with ABCA3 gene mutations with those without confirmed gene mutations and to establish the relationship between various ABCA3 gene mutations and variant RDS severity and outcomes.

Eligibility Criteria

Inclusion Criteria

  • infants ≥34 weeks' gestation
  • meet the fatal respiratory distress syndrome as following: (1) manifestations and chest radiograph are compatible with RDS; (2) at least 7days on invasive ventilation with FiO2 ≥60%, or persistent hypoxemic respiratory failure on FiO2 100% regardless of duration of invasive ventilation
  • undergone exome sequencing

Exclusion Criteria

  • culture-positive sepsis
  • cardiopulmonary malformations
  • pulmonary hypoplasia
  • known surfactant mutations such as SFTPB, SFTPC, CHPT1, LPCAT1 and PCYT1B were excluded.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04137783). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search